{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:43:10Z","timestamp":1768034590422,"version":"3.49.0"},"reference-count":30,"publisher":"Oceanside Publications Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>Eczematous dermatitis is a heterogeneous group of inflammatory skin disorders characterized by pruritus, erythema, and scaling. The most common subtype is atopic dermatitis (AD), which has a continuously rising prevalence, particularly within industrialized regions, e.g., the United\n States. Distinguishing AD from other dermatoses, particularly among adult patients with recalcitrant disease, can be challenging. Conditions such as allergic contact dermatitis may mimic or coexist with AD, which complicate both diagnosis and management. This diagnostic complexity has been\n unmasked with the introduction of targeted biologic therapies, including interleukin (IL) 4, IL-13, and IL-31 inhibitors, which have brought meaningful advances to the treatment landscape but also demands greater diagnostic precision. In this context, failure to identify overlapping or alternative\n conditions may delay optimal patient management or result in unnecessary therapeutic escalation to systemic agents, some of which have notable risk profiles. This review highlights the critical need for comprehensive diagnostic guidelines for the evaluation of adults with presumed AD, particularly\n those who exhibit an incomplete response to therapy. Diagnostic tools such as biopsies, cultures, laboratory studies, and expanded series patch testing have the potential to reveal underlying or comorbid conditions that fundamentally alter management strategies. With evidence that substantiates\n that a majority of patients with AD and with residual dermatitis on biologic therapy test positive for relevant contact allergen(s) on expanded series patch testing, the Clear, Patch, Avoid, and Treat strategy exemplifies a practical, stepwise framework for evaluating treatment-resistant eczematous\n dermatitis, which reinforces the clinical value of early diagnostic assessment and allergen avoidance. Establishing clear, evidence-based protocols is essential to support dermatologists and allergists in delivering individualized, high-quality care. In the absence of such guidelines, a methodical\n and comprehensive diagnostic approach remains the best tool to improve outcomes and reduce the burden of misdiagnosis in patients with complex or treatment-resistant dermatitis.<\/jats:p>","DOI":"10.2500\/aap.2026.47.250076","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:32:26Z","timestamp":1768019546000},"page":"12-16","source":"Crossref","is-referenced-by-count":0,"title":["Unmasking multifactorial dermatitis: The case for comprehensive diagnostic guidelines in adult atopic dermatitis"],"prefix":"10.2500","volume":"47","author":[{"given":"Eryn","family":"Patin","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi M.","family":"Murase","sequence":"additional","affiliation":[{"name":"Department of Genomics, University of California, Davis, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianne Shadi","family":"Kourosh","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny E.","family":"Murase","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco, San Francisco, California; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/jcm4050884","article-title":"Diagnosis of atopic dermatitis: mimics, overlaps, and complications","volume":"4","author":"Siegfried","year":"2015","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"crossref","first-page":"e2025071812","DOI":"10.1542\/peds.2025-071812","article-title":"Atopic dermatitis: update on skin-directed management: clinical report","volume":"155","author":"Schoch","year":"2025","journal-title":"Pediatrics"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljae266.002","article-title":"United States prevalence of atopic dermatitis in adults and pediatrics by race and ethnicity","volume":"191","author":"Alexis","year":"2024","journal-title":"Br J Dermatol"},{"key":"B4","first-page":"91","article-title":"The economic impact of atopic dermatitis","volume-title":"Adv Exp Med Biol.","volume":"1447","author":"Adamson","year":"2024"},{"key":"B5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/path.4810","article-title":"Molecular mechanisms in atopic eczema: insights gained from genetic studies","volume":"241","author":"Brown","year":"2017","journal-title":"J Pathol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41232-017-0044-7","article-title":"The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus","volume":"37","author":"Rerknimitr","year":"2017","journal-title":"Inflamm Regen"},{"key":"B7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2500\/aap.2025.46.240087","article-title":"Atopic dermatitis: best of guidelines and yardstick","volume":"46","author":"Boguniewicz","year":"2025","journal-title":"Allergy Asthma Proc"},{"key":"B8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B9","article-title":"Understanding the lived experience of eczema the \u201cvoice of the patient\u201d report on the eczema patient-focused drug development meeting","author":"McCleary","year":"2020"},{"key":"B10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/DER.0000000000000208","article-title":"A pragmatic approach to patch testing atopic dermatitis patients: clinical recommendations based on expert consensus opinion","volume":"27","author":"Chen","year":"2016","journal-title":"Dermatitis"},{"key":"B11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2500\/aap.2024.45.240019","article-title":"Evaluation of atopic diseases in patients with allergic contact dermatitis","volume":"45","author":"Sandoval","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"B12","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1111\/jdv.16445","article-title":"Eczema, targeted therapeutics, and allergy diagnostics: the need for greater clarity on what we are treating","volume":"34","author":"Chen","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"119S","DOI":"10.1002\/j.1875-9114.1991.tb02641.x","article-title":"Complications associated with immunosuppressive therapy and their management","volume":"11","author":"Min","year":"1991","journal-title":"Pharmacotherapy"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaip.2020.11.034","article-title":"Biologics for treatment of atopic dermatitis: current status and future prospect","volume":"9","author":"Ratchataswan","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jdcr.2018.08.027","article-title":"The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy","volume":"4","author":"Suresh","year":"2018","journal-title":"JAAD Case Rep"},{"key":"B16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/DER.0000000000000801","article-title":"Characterization of residual facial dermatitis during dupilumab therapy: a retrospective chart review to delineate the potential role of expanded series patch testing","volume":"33","author":"Ashbaugh","year":"2022","journal-title":"Dermatitis"},{"key":"B17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/DER.0000000000000900","article-title":"Clear, patch, avoid, treat as a diagnostic and therapeutic strategy for management of recalcitrant adult eczematous dermatitis","volume":"34","author":"Bai","year":"2023","journal-title":"Dermatitis"},{"key":"B18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jaad.2022.03.047","article-title":"Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab","volume":"87","author":"Bai","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1684\/ejd.2023.4450","article-title":"Facial tinea incognito: a clinical, dermoscopic and mycological study of 38 cases","volume":"33","author":"Kwak","year":"2023","journal-title":"Eur J Dermatol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"adv00878","DOI":"10.2340\/actadv.v103.5351","article-title":"Severe scabies: a French multi-centre study involving 95 patients with crusted and profuse disease and review of literature","volume":"103","author":"Skayem","year":"2023","journal-title":"Acata Derm Venereol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaad.2021.06.017","article-title":"Management of inadequate response and adverse effects to dupilumab in atopic dermatitis","volume":"86","author":"Narla","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaad.2019.09.028","article-title":"The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: a retrospective chart review","volume":"82","author":"Raffi","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1468-3083.2012.04635.x","article-title":"Guidelines for treatment of atopic eczema (atopic dermatitis) Part I","volume":"26","author":"Ring","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-023-08977-x","article-title":"Is food-triggered atopic dermatitis a form of systemic contact dermatitis?","volume":"66","author":"Ahuja","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"B26","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaip.2015.02.009","article-title":"Contact dermatitis: a practice parameter\u2013update 2015","volume":"3","author":"Fonacier","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B27","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaad.2014.08.038","article-title":"Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/cod.12432","article-title":"European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice","volume":"73","author":"Johansen","year":"2015","journal-title":"Contact Dermatitis"},{"key":"B29","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/pai.12463","article-title":"EAACI position paper for practical patch testing in allergic contact dermatitis in children","volume":"26","author":"de Waard-van der Spek","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0190-9622(03)02539-8","article-title":"Consensus conference on pediatric atopic dermatitis","volume":"49","author":"Eichenfield","year":"2003","journal-title":"J Am Acad Dermatol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000001\/art00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:33:06Z","timestamp":1768019586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.250076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["1088-5412(20260101)47:1L.12;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.250076","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}